Congenital microangiopathic hemolytic anemia and thrombocytopenia with unusually large von willebrand factor multimers and von willebrand factor-cleaving protease

American Journal of Pediatric Hematology/Oncology

Volumn 23, Issue 6, 2001, Pages 364-367

  Savaşan, Süreyya ^a   Taub, Jeffrey W ^a   Buck, Steven ^a   Botterill, Melinda ^a   Furlan, Miha ^b   Ravindranath, Yaddanapudi ^a  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Congenital; Endothelial cell apoptosis; Microangiopathic hemolytic anemia; Thrombocytopenia; Von Willebrand factor multimers

Indexed keywords

POLYMER; PROTEINASE; VON WILLEBRAND FACTOR;

APOPTOSIS; ARTICLE; CASE REPORT; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; PLASMA TRANSFUSION; PRESCHOOL CHILD; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; VASCULAR ENDOTHELIUM;

ADAM PROTEINS; ANEMIA, HEMOLYTIC, CONGENITAL; APOPTOSIS; BLOOD TRANSFUSION; CHILD, PRESCHOOL; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INFANT; METALLOENDOPEPTIDASES; THROMBOCYTOPENIA; VON WILLEBRAND FACTOR;

EID: 0034847605     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200108000-00008     Document Type: Article

References (24)

1. Remuzzi G. HUS and TTP: variable expression of a single entity. Kidney Int 1987; 32:292-308.
2. Schulman I, Pierce M, Lukens A, et al. Studies on thrombopoiesis. I. A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency. Blood 1960; 16:943-57.
3. Upshaw JD. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med 1978; 298:1350-2.
4. Shinohara T, Miyamura S, Suzuki E, et al. Congenital microangiopathic haemolytic anemia: report of a Japanese girl. Eur J Pediatr 1982; 138:191-3.
5. Miura M, Koizumi S, Nakamura K, et al. Efficacy of several plasma components in a young boy with chronic thrombocytopenia and haemolytic anemia who responds repeatedly to normal plasma infusions. Am J Hematol 1984; 17:307-19.
6. Rennard S, Abe S. Decreased cold-insoluble globulin in congenital thrombocytopenia (Upshaw-Schulman syndrome). N Engl J Med 1979; 300:368.
7. Laurence J, Mitra D, Steiner M, et al. Plasma from patients with idiopathic and human immunodeficiency virus-associated thrombotic thrombocytopenic purpura induces apoptosis in microvascular endothelial cells. Blood 1996; 87:3245-54.
8. Furlan M, Robles R, Solenthaler M, et al. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89:3097-103.
9. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uraemic syndrome. N Engl J Med 1998; 339:1578-84.
10. Balasa V, Gruppo RA, Tsai HM. Familial chronic thrombotic thrombocytopenic purpura (TTP) due to vWF-cleaving metalloproteinase deficiency in 2 families [abstract]. J Pediatr Hematol Oncol 1999; 21:332.
11. Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87:4223-34.
12. Bordron A, Dueymes M, Levy Y, et al. The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. J Clin Invest 1998; 101:2029-35.
13. Chintagumpala MM, Hurwitz RL, Moake JL, et al. Chronic relapsing thrombotic thrombocytopenic purpura in infants with large von Willebrand factor multimers during remission. J Pediatr 1992; 120:49-53.
14. Daghistani D, Jimenez JJ, Moake JL, et al. Familial infantile thrombotic thrombocytopenic purpura. J Pediatr Hematol Oncol 1996; 18:171-4.
15. Azuno Y, Kaku K, Shino K, et al. A congenital variant of thrombotic thrombocytopenic purpura in two siblings. Intern Med 1994; 33:752-8.
16. Maes P, Brichard B, Vermylen C, et al. Chronic relapsing thrombotic thrombocytopenic purpura: three case reports and update of the pathogenesis and therapeutic modalities. Eur J Pediatr 1998; 157:468-72.
17. Moake JL, McPherson PD. Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. Am J Med 1989; 87 (3N):9N-15N.
18. Mannucci PM, Lombardi R, Lattuada A, et al. Enhanced proteolysis of plasma von Willebrand factor (vWF) in thrombotic thrombocytopenic purpura (TTP) and the hemolytic uremic syndrome. Blood 1989; 74:978-83.
19. Byrnes JJ, Moake JL. Thrombotic thrombocytopenic purpura and the haemolytic-uraemic syndrome: evolving concepts of pathogenesis and therapy. Clin Haematol 1986; 15:413-42.
20. Tsai H-M, Lian EC-Y. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339:1585-94.
21. Häberle J, Kehrel B, Ritter J, et al. New strategies in diagnosis and treatment of thrombotic thrombocytopenic purpura: case report and review. Eur J Pediatr 1999; 158:883-7.
22. Furlan M, Robles R, Morselli B, et al. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1999; 81:8-13.
23. Bombeli T, Karsan A, Tait JF, et al. Apoptotic vascular endothelial cells become procoagulant. Blood 1997; 89:2429-42.
24. Mitra D, Jaffe EA, Weksler B, et al. Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells. Blood 1997; 89:1224-34.